AFMD stock icon

Affimed
AFMD

$5.16
0.1%

Market Cap: 78.5M

 

About: Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Employees: 78

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

400% more call options, than puts

Call options by funds: $5K | Put options by funds: $1K

12.57% less ownership

Funds ownership: 30.71% [Q4 2023] → 18.14% (-12.57%) [Q1 2024]

36% less funds holding

Funds holding: 67 [Q4 2023] → 43 (-24) [Q1 2024]

50% less capital invested

Capital invested by funds: $28.7M [Q4 2023] → $14.4M (-$14.3M) [Q1 2024]

92% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 26

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 41

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
3%
downside
Avg. target
$14.17
175%
upside
High target
$25
385%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
Laidlaw & Co.
Yale Jen
385%upside
$25
Buy
Maintained
13 Jun 2024
HC Wainwright & Co.
Swayampakula Ramakanth
94%upside
$10
Buy
Reiterated
13 Jun 2024
HC Wainwright & Co.
Swayampakula Ramakanth
94%upside
$10
Buy
Reiterated
3 Jun 2024
Wells Fargo
Yanan Zhu
385%upside
$25
Overweight
Maintained
1 Apr 2024
Stifel
Bradley Canino
3%downside
$5
Hold
Maintained
1 Apr 2024

Financial journalist opinion